Ifit2 deficiency results in uncontrolled neurotropic coronavirus replication and enhanced encephalitis via impaired alpha/beta interferon induction in macrophages

Journal of Virology

Volumn 88, Issue 2, 2014, Pages 1051-1064

  Butchi, Niranjan B ^a   Hinton, David R ^b   Stohlman, Stephen A ^a   Kapil, Parul ^a   Fensterl, Volker ^a   Sen, Ganes C ^a   Bergmann, Cornelia C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHEMOKINE; CYTOKINE; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN IFIT2; PROTEIN ISG15; PROTEIN PKR; TETRATRICOPEPTIDE REPEAT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; CORONAVIRUS INFECTION; CYTOKINE PRODUCTION; DISEASE SEVERITY; EX VIVO STUDY; GENE EXPRESSION; MACROPHAGE; MOUSE; MURINE HEPATITIS CORONAVIRUS; MURINE HEPATITIS CORONAVIRUS (STRAIN A59); NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SURVIVAL RATE; VIRUS ENCEPHALITIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; WILD TYPE;

ANIMALS; CENTRAL NERVOUS SYSTEM; ENCEPHALITIS; FEMALE; INTERFERON-ALPHA; INTERFERON-BETA; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MURINE HEPATITIS VIRUS; PROTEINS; RODENT DISEASES; VIRAL TROPISM;

EID: 84891696320     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02272-13     Document Type: Article

References (66)

1. Kumar H, Kawai T, Akira S. 2009. Pathogen recognition in the innate immune response. Biochem. J. 420:1-16. http://dx.doi.org/10.1042/BJ20090272.
2. Wilkins C, Gale M, Jr. 2010. Recognition of viruses by cytoplasmic sensors. Curr. Opin. Immunol. 22:41-47. http://dx.doi.org/10.1016/j.coi.2009.12.003.
3. Samuel CE. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14:778-809. http://dx.doi.org/10.1128/CMR.14.4.778-809.2001.
4. Schoggins JW, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1:519-525. http://dx.doi.org/10.1016/j.coviro.2011.10.008.
5. Cho H, Proll SC, Szretter KJ, Katze MG, Gale M, Jr, Diamond MS. 2013. Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-stranded RNA viruses. Nat. Med. 19:458-464. http://dx.doi.org/10.1038/nm.3108.
6. Zhao L, Birdwell LD, Wu A, Elliott R, Rose KM, Phillips JM, Li Y, Grinspan J, Silverman RH, Weiss SR. 2013. Cell-type-specific activation of the oligoadenylate synthetase-RNase L pathway by a murine coronavirus. J. Virol. 87:8408-8418. http://dx.doi.org/10.1128/JVI.00769-13.
7. Diamond MS, Farzan M. 2013. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat. Rev. Immunol. 13:46-57.
8. Fensterl V, Sen GC. 2011. The ISG56/IFIT1 gene family. J. Interferon Cytokine Res. 31:71-78. http://dx.doi.org/10.1089/jir.2010.0101.
9. Wacher C, Muller M, Hofer MJ, Getts DR, Zabaras R, Ousman SS, Terenzi F, Sen GC, King NJ, Campbell IL. 2007. Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J. Virol. 81:860-871. http://dx.doi.org/10.1128/JVI.01167-06.
10. Terenzi F, Pal S, Sen GC. 2005. Induction and mode of action of the viral stress-inducible murine proteins, P56 and P54. Virology 340:116-124. http://dx.doi.org/10.1016/j.virol.2005.06.011.
11. Hui DJ, Bhasker CR, Merrick WC, Sen GC. 2003. Viral stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3 with the ternary complex eIF2 · GTP · Met-tRNAi. J. Biol. Chem. 278:39477-39482. http://dx.doi.org/10.1074/jbc.M305038200.
12. Terenzi F, Hui DJ, Merrick WC, Sen GC. 2006. Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J. Biol. Chem. 281:34064-34071. http://dx.doi.org/10.1074/jbc.M605771200.
13. Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, Burkard TR, Burckstummer T, Stefanovic A, Krieger S, Bennett KL, Rulicke T, Weber F, Colinge J, Muller M, Superti-Furga G. 2011. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat. Immunol. 12:624-630. http://dx.doi.org/10.1038/ni.2048.
14. Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J, Lin TY, Schneller S, Zust R, Dong H, Thiel V, Sen GC, Fensterl V, Klimstra WB, Pierson TC, Buller RM, Gale M, Jr, Shi PY, Diamond MS. 2010. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468:452-456. http://dx.doi.org/10.1038/nature09489.
15. Zust R, Cervantes-Barragan L, Habjan M, Maier R, Neuman BW, Ziebuhr J, Szretter KJ, Baker SC, Barchet W, Diamond MS, Siddell SG, Ludewig B, Thiel V. 2011. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 12:137-143. http://dx.doi.org/10.1038/ni.1979.
16. Yang Z, Liang H, Zhou Q, Li Y, Chen H, Ye W, Chen D, Fleming J, Shu H, Liu Y. 2012. Crystal structure of ISG54 reveals a novel RNA binding structure and potential functional mechanisms. Cell Res. 22:1328-1338. http://dx.doi.org/10.1038/cr.2012.111.
17. Li Y, Li C, Xue P, Zhong B, Mao AP, Ran Y, Chen H, Wang YY, Yang F, Shu HB. 2009. ISG56 is a negative-feedback regulator of virus-triggered signaling and cellular antiviral response. Proc. Natl. Acad. Sci. U. S. A. 106:7945-7950. http://dx.doi.org/10.1073/pnas.0900818106.
18. Liu XY, Chen W, Wei B, Shan YF, Wang C. 2011. IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J. Immunol. 187:2559-2568. http://dx.doi.org/10.4049/jimmunol.1100963.
19. Siegfried A, Berchtold S, Manncke B, Deuschle E, Reber J, Ott T, Weber M, Kalinke U, Hofer MJ, Hatesuer B, Schughart K, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Weber F, Hornef MW, Autenrieth IB, Bohn E. 2013. IFIT2 is an effector protein of type I IFN-mediated amplification of lipopolysaccharide (LPS)-induced TNF-alpha secretion and LPS-induced endotoxin shock. J. Immunol. 191:3913-3921. http://dx.doi.org/10.4049/jimmunol.1203305.
20. Fensterl V, Wetzel JL, Ramachandran S, Ogino T, Stohlman SA, Bergmann CC, Diamond MS, Virgin HW, Sen GC. 2012. Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog. 8:e1002712. http://dx.doi.org/10.1371/journal.ppat.1002712.
21. Cho H, Shrestha B, Sen GC, Diamond MS. 2013. A role for ifit2 in restricting West Nile virus infection in the brain. J. Virol. 87:8363-8371. http://dx.doi.org/10.1128/JVI.01097-13.
22. Fiette L, Aubert C, Muller U, Huang S, Aguet M, Brahic M, Bureau JF. 1995. Theiler's virus infection of 129Sv mice that lack the interferon alpha/beta or interferon gamma receptors. J. Exp. Med. 181:2069-2076. http://dx.doi.org/10.1084/jem.181.6.2069.
23. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921. http://dx.doi.org/10.1126/science.8009221.
24. Ryman KD, Klimstra WB, Nguyen KB, Biron CA, Johnston RE. 2000. Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J. Virol. 74:3366-3378. http://dx.doi.org/10.1128/JVI.74.7.3366-3378.2000.
25. Samuel MA, Diamond MS. 2005. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79:13350-13361. http://dx.doi.org/10.1128/JVI.79.21.13350-13361.2005.
26. Cervantes-Barragan L, Zust R, Weber F, Spiegel M, Lang KS, Akira S, Thiel V, Ludewig B. 2007. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood 109:1131-1137.
27. Ireland DD, Stohlman SA, Hinton DR, Atkinson R, Bergmann CC. 2008. Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells. J. Virol. 82:300-310. http://dx.doi.org/10.1128/JVI.01794-07.
28. Ireland DD, Stohlman SA, Hinton DR, Kapil P, Silverman RH, Atkinson RA, Bergmann CC. 2009. RNase L mediated protection from virus induced demyelination. PLoS Pathog. 5:e1000602. http://dx.doi.org/10.1371/journal.ppat.1000602.
29. Szretter KJ, Daniels BP, Cho H, Gainey MD, Yokoyama WM, Gale M, Jr, Virgin HW, Klein RS, Sen GC, Diamond MS. 2012. 2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog. 8:e1002698. http://dx.doi.org/10.1371/journal.ppat.1002698.
30. Zhao L, Jha BK, Wu A, Elliott R, Ziebuhr J, Gorbalenya AE, Silverman RH, Weiss SR. 2012. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe 11:607-616. http://dx.doi.org/10.1016/j.chom.2012.04.011.
31. Kristiansen H, Gad HH, Eskildsen-Larsen S, Despres P, Hartmann R. 2011. The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities. J. Interferon Cytokine Res. 31:41-47. http://dx.doi.org/10.1089/jir.2010.0107.
32. Eriksson KK, Cervantes-Barragan L, Ludewig B, Thiel V. 2008. Mouse hepatitis virus liver pathology is dependent on ADP-ribose-1″-phosphatase, a viral function conserved in the alpha-like supergroup. J. Virol. 82:12325-12334. http://dx.doi.org/10.1128/JVI.02082-08.
33. Rempel JD, Murray SJ, Meisner J, Buchmeier MJ. 2004. Differential regulation of innate and adaptive immune responses in viral encephalitis. Virology 318:381-392. http://dx.doi.org/10.1016/j.virol.2003.09.023.
34. Savarin C, Stohlman SA, Rietsch AM, Butchi N, Ransohoff RM, Bergmann CC. 2011. MMP9 deficiency does not decrease blood-brain barrier disruption, but increases astrocyte MMP3 expression during viral enceph-alomyelitis. Glia 59:1770-1781. http://dx.doi.org/10.1002/glia.21222.
35. Fleming JO, Trousdale MD, el-Zaatari FA, Stohlman SA, Weiner LP. 1986. Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies. J. Virol. 58:869-875.
36. Kapil P, Butchi NB, Stohlman SA, Bergmann CC. 2012. Oligodendroglia are limited in type I interferon induction and responsiveness in vivo. Glia 60:1555-1566. http://dx.doi.org/10.1002/glia.22375.
37. Gonzalez JM, Bergmann CC, Fuss B, Hinton DR, Kangas C, Macklin WB, Stohlman SA. 2005. Expression of a dominant negative IFN-gammareceptor on mouse oligodendrocytes. Glia 51:22-34. http://dx.doi.org/10.1002/glia.20182.
38. Phares TW, Marques CP, Stohlman SA, Hinton DR, Bergmann CC. 2011. Factors supporting intrathecal humoral responses following viral encephalomyelitis. J. Virol. 85:2589-2598. http://dx.doi.org/10.1128/JVI.02260-10.
39. Bergmann CC, Parra B, Hinton DR, Chandran R, Morrison M, Stohlman SA. 2003. Perforin-mediated effector function within the central nervous system requires IFN-gamma-mediated MHC up-regulation. J. Immunol. 170:3204-3213.
40. Phares TW, Ramakrishna C, Parra GI, Epstein A, Chen L, Atkinson R, Stohlman SA, Bergmann CC. 2009. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J. Immunol.182:5430-5438. http://dx.doi.org/10.4049/jimmunol.0803557.
41. Uze G, Di Marco S, Mouchel-Vielh E, Monneron D, Bandu MT, Horisberger MA, Dorques A, Lutfalla G, Mogensen KE. 1994. Domains of interaction between alpha interferon and its receptor components. J. Mol. Biol. 243:245-257. http://dx.doi.org/10.1006/jmbi.1994.1651.
42. Terenzi F, White C, Pal S, Williams BR, Sen GC. 2007. Tissue-specific and inducer-specific differential induction of ISG56 and ISG54 in mice. J. Virol. 81:8656-8665. http://dx.doi.org/10.1128/JVI.00322-07.
43. Reiss CS, Plakhov IV, Komatsu T. 1998. Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann. N. Y. Acad. Sci. 855:751-761. http://dx.doi.org/10.1111/j.1749-6632.1998.tb10655.x.
44. van den Pol AN. 2006. Viral infections in the developing and mature brain. Trends Neurosci. 29:398-406. http://dx.doi.org/10.1016/j.tins.2006.06.002.
45. van den Pol AN, Dalton KP, Rose JK. 2002. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J. Virol. 76:1309-1327. http://dx.doi.org/10.1128/JVI.76.3.1309-1327.2002.
46. Vernon PS, Griffin DE. 2005. Characterization of an in vitro model of alphavirus infection of immature and mature neurons. J. Virol. 79:3438-3447. http://dx.doi.org/10.1128/JVI.79.6.3438-3447.2005.
47. Lavi E, Gilden DH, Highkin MK, Weiss SR. 1984. Persistence of mouse hepatitis virus A59 RNA in a slow virus demyelinating infection in mice as detected by in situ hybridization. J. Virol. 51:563-566.
48. Miura TA, Travanty EA, Oko L, Bielefeldt-Ohmann H, Weiss SR, Beauchemin N, Holmes KV. 2008. The spike glycoprotein of murine coronavirus MHV-JHM mediates receptor-independent infection and spread in the central nervous systems of Ceacam1a-/-mice. J. Virol. 82:755-763. http://dx.doi.org/10.1128/JVI.01851-07.
49. Phillips JJ, Chua MM, Lavi E, Weiss SR. 1999. Pathogenesis of chimeric MHV4/MHV-A59 recombinant viruses: the murine coronavirus spike protein is a major determinant of neurovirulence. J. Virol. 73:7752-7760.
50. Roth-Cross JK, Bender SJ, Weiss SR. 2008. Murine coronavirus mouse hepatitis virus is recognized by MDA5 and induces type I interferon in brain macrophages/microglia. J. Virol. 82:9829-9838. http://dx.doi.org/10.1128/JVI.01199-08.
51. Cervantes-Barragan L, Kalinke U, Zust R, Konig M, Reizis B, Lopez-Macias C, Thiel V, Ludewig B. 2009. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J. Immunol. 182:1099-1106.
52. Gonzalez JM, Bergmann CC, Ramakrishna C, Hinton DR, Atkinson R, Hoskin J, Macklin WB, Stohlman SA. 2006. Inhibition of interferon-gamma signaling in oligodendroglia delays coronavirus clearance without altering demyelination. Am. J. Pathol. 168:796-804. http://dx.doi.org/10.2353/ajpath.2006.050496.
53. Hindinger C, Bergmann CC, Hinton DR, Phares TW, Parra GI, Hussain S, Savarin C, Atkinson RD, Stohlman SA. 2012. IFN-gamma signaling to astrocytes protects from autoimmune mediated neurological disability. PLoS One 7:e42088. http://dx.doi.org/10.1371/journal.pone.0042088.
54. Hua LL, Kim MO, Brosnan CF, Lee SC. 2002. Modulation of astrocyte inducible nitric oxide synthase and cytokine expression by interferon beta is associated with induction and inhibition of interferon gamma-activated sequence binding activity. J. Neurochem. 83:1120-1128. http://dx.doi.org/10.1046/j.1471-4159.2002.01226.x.
55. Okada K, Kuroda E, Yoshida Y, Yamashita U, Suzumura A, Tsuji S. 2005. Effects of interferon-beta on the cytokine production of astrocytes. J. Neuroimmunol. 159:48-54. http://dx.doi.org/10.1016/j.jneuroim.2004.09.013.
56. Savarin C, Stohlman SA, Atkinson R, Ransohoff RM, Bergmann CC. 2010. Monocytes regulate T cell migration through the glia limitans during acute viral encephalitis. J. Virol. 84:4878-4888. http://dx.doi.org/10.1128/JVI.00051-10.
57. Servant MJ, Grandvaux N, tenOever BR, Duguay D, Lin R, Hiscott J. 2003. Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA. J. Biol. Chem. 278:9441-9447. http://dx.doi.org/10.1074/jbc.M209851200.
58. Flodstrom-Tullberg M, Hultcrantz M, Stotland A, Maday A, Tsai D, Fine C, Williams B, Silverman R, Sarvetnick N. 2005. RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection. J. Immunol. 174:1171-1177.
59. Samuel MA, Whitby K, Keller BC, Marri A, Barchet W, Williams BR, Silverman RH, Gale M, Jr, Diamond MS. 2006. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 80:7009-7019. http://dx.doi.org/10.1128/JVI.00489-06.
60. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C, Silverman RH. 1997. Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. EMBO J. 16:6355-6363. http://dx.doi.org/10.1093/emboj/16.21.6355.
61. Loo YM, Gale M, Jr. 2011. Immune signaling by RIG-I-like receptors. Immunity 34:680-692. http://dx.doi.org/10.1016/j.immuni.2011.05.003.
62. Lu LL, Puri M, Horvath CM, Sen GC. 2008. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J. Biol. Chem. 283:14269-14276. http://dx.doi.org/10.1074/jbc.M710089200.
63. White TC, Yi Z, Hogue BG. 2007. Identification of mouse hepatitis coronavirus A59 nucleocapsid protein phosphorylation sites. Virus Res. 126:139-148. http://dx.doi.org/10.1016/j.virusres.2007.02.008.
64. Wilbur SM, Nelson GW, Lai MM, McMillan M, Stohlman SA. 1986. Phosphorylation of the mouse hepatitis virus nucleocapsid protein. Biochem. Biophys. Res. Commun. 141:7-12. http://dx.doi.org/10.1016/S0006-291X(86)80326-6.
65. Wang G, Chen G, Zheng D, Cheng G, Tang H. 2011. PLP2 of mouse hepatitis virus A59 (MHV-A59) targets TBK1 to negatively regulate cellular type I interferon signaling pathway. PLoS One 6:e17192. http://dx.doi.org/10.1371/journal.pone.0017192.
66. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond MS, Colonna M. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. U. S. A. 103:8459-8464. http://dx.doi.org/10.1073/pnas.0603082103.